BIO vs RVTY
Bio-Rad Laboratories, Inc. (BIO) and Revvity, Inc. (RVTY) are both filed with the SEC under Laboratory Analytical Instruments. RVTY is 1.3× BIO's size by market cap ($14.5B against $10.8B); RVTY trades at the higher fiscal-year P/E (62.7× against 14.0×); BIO reports the higher net margin (29.4% against 8.4%); BIO grew sales faster over three years (-2.7% against -4.8%); and over the past year RVTY returned +44.7% against BIO's +32.0%.
| BIO | RVTY | |
|---|---|---|
| Last close | $387.70 | $128.80 |
| Market cap | $10.8B | $14.5B |
| P/E (FY) | 14.0× | 62.7× |
| P/S | 4.2× | 5.1× |
| EV/EBITDA | 49.2× | 22.0× |
| Gross margin | 51.9% | 69.7% |
| Operating margin | 1.8% | 12.5% |
| Net margin | 29.4% | 8.4% |
| Return on equity | 10.8% | 3.2% |
| Sales growth (3y) | -2.7% | -4.8% |
| EPS growth (3y) | — | -22.8% |
| Dividend yield | — | 0.2% |
| 1-year return | +32.0% | +44.7% |
Screener snapshot — prices as of 2026-08-28. Each side's last close is the most recent session the snapshot holds for that company, which can be an earlier one, and its 1-year return is measured to that close. Market caps struck on 2026-08-27. Last close, market cap and the 1-year return are price figures; every other row is computed over the company's latest filed fiscal year, and the two differ: BIO FY2025 (ended 2025-12-31); RVTY FY2025 (ended 2025-12-28). — not published for this company. A ratio goes unpublished for more than one reason: a component the calculation needs is not on file, the filing does not tag the line it is read from, or the calculation is not defined on the filed basis — EV/EBITDA is not printed on non-positive EBITDA, and return on equity is not computed on a zero or negative equity base.
Who holds them, and who has traded them
| BIO | RVTY | |
|---|---|---|
| Institutional holders (13F) | 390 | 498 |
| Insider buyers − sellers (180d) | — | -1 |
| Congressional trades disclosed (180d) | 0 | 2 |
| Executive-branch officials on file — trades disclosed (180d) | 0 | 2 |
Counts only. The congressional figures count transactions dated in the trailing 180 days and disclosed in STOCK Act periodic transaction reports; amounts are filed as ranges and are never summed. The executive-branch figures count the same window of transactions, and they are scoped to one roster. The officials OGE posts for direct download. Insider buyers − sellers counts distinct people filing open-market Form 4 purchases minus distinct people filing open-market sales over the trailing 180 days, capped at ±5. — no open-market Form 4 purchases or sales in the window.
BIO vs RVTY: common questions
- Is BIO bigger than RVTY?
- RVTY carries the larger market cap — $14.5B against $10.8B, both struck on 2026-08-27.
- Which trades at a higher P/E, BIO or RVTY?
- RVTY, at a fiscal-year 62.7× against 14.0× for BIO. Both are price ÷ latest full-year diluted earnings per share, not a trailing-twelve-month P/E.
- How have BIO and RVTY performed over the past year?
- RVTY returned +44.7% and BIO +32.0%, measured on the trailing calendar year to the last close.
- How many institutions hold BIO and RVTY?
- 390 13F filers report a position in BIO and 498 in RVTY, on the latest quarter in the panel.
- Are BIO and RVTY in the same industry?
- Both are filed with the SEC under Laboratory Analytical Instruments, which is the classification this pairing is built on.
BIO overview → · RVTY overview → · BIO institutional ownership → · RVTY institutional ownership → · Congress and RVTY → · Executive branch and RVTY →
More in Laboratory Analytical Instruments: A vs BIO · A vs ILMN · A vs RVTY · A vs WAT
Stock comparisons lists every pair this site publishes.
Source: SPZCO — https://spzco.com/vs/bio-vs-rvty